Clinical Trial Update: A Phase I/IIa Sporozoite Challenge Study to Assess the Efficacy of Candidate Combination Malaria Vaccine Approaches Using the ChAd63 and MVA Vectors Encoding the Antigens ME-TRAP, CS and AMA1 [Phase 1, Phase 2]

View source ↗

Summary

A Phase I/IIa sporozoite challenge trial conducted by the University of Oxford to evaluate malaria vaccine approaches using ChAd63 and MVA vectors encoding ME-T…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malaria

Drugs mentioned

• ChAd63 (chimpanzee adenovirus vector encoding malaria antigens ME-TRAP, CS, AMA1)
• MVA (Modified Vaccinia Ankara vector encoding malaria antigens ME-TRAP, CS, AMA1)

Snippet

Sponsor: University of Oxford | Conditions: Plasmodium Falciparum Malaria | Phase 1, Phase 2 | Status: COMPLETED